Astrana Health Inc. Common Stock (ASTH) Stock
Key stats
- Market cap
- $1.64B
- Price / Earnings ratio
- 33.8x
- EPS (TTM)
- $1.08
- Volume
- Loading
- 52-week high
- $51.60
- 52-week low
- $18.08
Source: third-party data provider, as of November 13, 2026
Compare with ASTH
Recent news

Why Astrana Health, Inc. (ASTH) is Poised to Beat Earnings Estimates Again
Why Astrana Health, Inc. (ASTH) is Poised to Beat Earnings Estimates Again
ASTH

ASTH Investors Have Opportunity to Join Astrana Health, Inc. Fraud Investigation with SBS Law
ASTH Investors Have Opportunity to Join Astrana Health, Inc. Fraud Investigation with SBS Law
ASTH

PRIVACY ALERT: AWKO Law Investigating Astrana Health Data Breach
PRIVACY ALERT: AWKO Law Investigating Astrana Health Data Breach
ASTH

Astrana Health, Inc. (ASTH) Q2 Earnings Top Estimates
Astrana Health, Inc. (ASTH) Q2 Earnings Top Estimates
ASTH
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 37.09
- MACD 12/26/9
- -0.78
- EMA 9 of MACD
- -0.23
- MACD histogram
- -0.55
- SMA 50
- $36.67
- Price below SMA 50
- EMA 50
- $36.80
- Price below EMA 50
- SMA 200
- $34.21
- Price below SMA 200
- EMA 200
- $33.28
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Why Astrana Health, Inc. (ASTH) is Poised to Beat Earnings Estimates Again
Why Astrana Health, Inc. (ASTH) is Poised to Beat Earnings Estimates Again
ASTH

ASTH Investors Have Opportunity to Join Astrana Health, Inc. Fraud Investigation with SBS Law
ASTH Investors Have Opportunity to Join Astrana Health, Inc. Fraud Investigation with SBS Law
ASTH

PRIVACY ALERT: AWKO Law Investigating Astrana Health Data Breach
PRIVACY ALERT: AWKO Law Investigating Astrana Health Data Breach
ASTH

Astrana Health, Inc. (ASTH) Q2 Earnings Top Estimates
Astrana Health, Inc. (ASTH) Q2 Earnings Top Estimates
ASTH

Astrana Health Q2 Earnings Call Highlights
Astrana Health Q2 Earnings Call Highlights
ASTH

Astrana Health, Inc. (ASTH) Surges 7.3%: Is This an Indication of Further Gains?
Astrana Health, Inc. (ASTH) Surges 7.3%: Is This an Indication of Further Gains?
ASTH

Astrana Health Says Prospect Deal Is Ahead of Schedule as Q1 Trends Beat Expectations
Astrana Health Says Prospect Deal Is Ahead of Schedule as Q1 Trends Beat Expectations
ASTH

Astrana Health, Inc. (ASTH) Surpasses Q1 Earnings and Revenue Estimates
Astrana Health, Inc. (ASTH) Surpasses Q1 Earnings and Revenue Estimates
ASTH

Is the Options Market Predicting a Spike in Astrana Health Stock?
Is the Options Market Predicting a Spike in Astrana Health Stock?
ASTH

Astrana Health, Inc. (ASTH) Q4 Earnings and Revenues Surpass Estimates
Astrana Health, Inc. (ASTH) Q4 Earnings and Revenues Surpass Estimates
ASTH
News tone: automated (AI) classification of the article's content, not a price prediction.
About Astrana Health Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Brandon K. Sim M.S. | President & CEO | 1994 |
| Dr. Kenneth T. Sim F.A.C.S., M.D. | Co-Founder & Executive Chairman | 1954 |
| Mr. Chandan Basho M.B.A. | CFO, COO & Corporate Secretary | 1983 |
| Dr. Thomas S. Lam M.D., M.P.H. | Co-Founder & Vice Chairman | 1949 |
| Mr. John Vong CPA, CGMA, M.B.A. | Senior VP of Accounting & Principal Accounting Officer | 1973 |
| Ms. Rita Pew M.B.A. | Chief People Officer | — |
| Dr. WaiChow Young M.D., M.P.H. | Senior Vice President of Health Affairs | 1948 |
| Dr. Jeremy R. Jackson M.D. | Chief Quality Officer | — |
| Ms. Jaime Melkonoff M.B.A. | President of AstranaCare - Texas | — |
| Mr. Paul Van Duine M.B.A. | Senior Vice President of Contracting | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 37.09
- MACD 12/26/9
- -0.78
- EMA 9 of MACD
- -0.23
- MACD histogram
- -0.55
- SMA 50
- $36.67
- Price below SMA 50
- EMA 50
- $36.80
- Price below EMA 50
- SMA 200
- $34.21
- Price below SMA 200
- EMA 200
- $33.28
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $45.00
- Average
- $49.33
- High
- $53.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | +5.3 | -3.6 | -11.6 | +11.2 | -4.0 | +32.0 | -7.3 | +22.2 | -7.0 | -20.7 | -29.6 | |
| 2025 | +14.5 | -30.0 | +17.1 | +4.4 | -21.2 | +1.6 | -4.8 | +48.2 | -11.1 | +10.8 | -30.2 | +7.0 |
| 2026 | -9.8 | -8.9 | -6.8 | +39.3 | +7.8 | +22.9 | -28.6 | +6.1 | -7.8 | +4.6 | -10.7 |



